Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 27, 2015, Pages 8409-8414

  Henneman, Linda ^a   Van Miltenburg, Martine H ^a   Michalak, Ewa M ^a   Braumuller, Tanya M ^a   Jaspers, Janneke E ^a   Drenth, Anne Paulien ^a   De Korte Grimmerink, Renske ^a   Gogola, Ewa ^a   Szuhai, Karoly ^b   Schlicker, Andreas ^a   Ali, Rahmen Bin ^a   Pritchard, Colin ^a   Huijbers, Ivo J ^a   Berns, Anton ^a   Rottenberg, Sven ^a   Jonkers, Jos ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

BRCA1; Breast cancer; Mouse model; PARP; Resistance

Indexed keywords

BRCA1 PROTEIN; MULTIDRUG RESISTANCE PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OLAPARIB; ENZYME INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; BREAST CANCER; CARCINOSARCOMA; CONTROLLED STUDY; DNA CROSS LINKING; DRUG RESPONSE; FEMALE; GENETICALLY ENGINEERED MOUSE STRAIN; METAPLASIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; ANIMAL; BREAST NEOPLASMS; C57BL MOUSE; DEFICIENCY; DISEASE MODEL; DRUG RESISTANCE; GENETICS; HUMAN; KNOCKOUT MOUSE; MAMMARY NEOPLASMS, EXPERIMENTAL; METABOLISM; SURVIVAL ANALYSIS;

ANIMALS; BRCA1 PROTEIN; BREAST NEOPLASMS; CARCINOSARCOMA; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; METAPLASIA; MICE, INBRED C57BL; MICE, KNOCKOUT; P-GLYCOPROTEINS; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; POLY(ADP-RIBOSE) POLYMERASES; SURVIVAL ANALYSIS;

EID: 84936806860     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1500223112     Document Type: Article

References (37)

1. Sonnenblick A, de Azambuja E, Azim HA, Piccart M (2015) An update on PARP inhibitors-moving to the adjuvant setting. Nat Rev Clin Oncol 12(1):27-41.
2. Tutt A, et al. (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial. Lancet 376(9737):235-244.
3. Fong PC, et al. (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361(2):123-134.
4. Hollier BG, Evans K, Mani SA (2009) The epithelial-to-mesenchymal transition and cancer stem cells: A coalition against cancer therapies. J Mammary Gland Biol Neoplasia 14(1):29-43.
5. Taube JH, et al. (2010) Core epithelial-to-mesenchymal transition interactome geneexpression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci USA 107(35):15449-15454.
6. Borst P (2012) Cancer drug pan-resistance: Pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what? Open Biol 2(5):120066.
7. Foroni C, Broggini M, Generali D, Damia G (2012) Epithelial-mesenchymal transition and breast cancer: Role, molecular mechanisms and clinical impact. Cancer Treat Rev 38(6):689-697.
8. Hennessy BT, et al. (2009) Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 69(10):4116-4124.
9. Jung S-Y, et al. (2010) Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer. Breast Cancer Res Treat 120(3): 627-637.
10. Turner NC, et al. (2007) BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 26(14):2126-2132.
11. van Miltenburg MH, Jonkers J (2012) Using genetically engineered mouse models to validate candidate cancer genes and test new therapeutic approaches. Curr Opin Genet Dev 22(1):21-27.
12. Huijbers IJ, Krimpenfort P, Berns A, Jonkers J (2011) Rapid validation of cancer genes in chimeras derived from established genetically engineered mouse models. BioEssays 33(9):701-710.
13. Huijbers IJ, et al. (2014) Rapid target gene validation in complex cancer mouse models using re-derived embryonic stem cells. EMBO Mol Med 6(2):212-225.
14. Liu X, et al. (2007) Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci USA 104(29):12111-12116.
15. Ishikawa H, Banzai M, Yamauchi T (1999) Developmental retardation of XO mouse embryos at mid-gestation. J Reprod Fertil 115(2):263-267.
16. Burgoyne PS, Ojarikre OA, Turner JMA (2002) Evidence that postnatal growth retardation in XO mice is due to haploinsufficiency for a non-PAR X gene. Cytogenet Genome Res 99(1-4):252-256.
17. Beard C, Hochedlinger K, Plath K, Wutz A, Jaenisch R (2006) Efficient method to generate single-copy transgenic mice by site-specific integration in embryonic stem cells. Genesis 44(1):23-28.
18. Zhang Z, et al. (2014) Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer. Clin Cancer Res 20(17):4559-4573.
19. La Monica S, et al. (2013) Gefitinib inhibits invasive phenotype and epithelialmesenchymal transition in drug-resistant NSCLC cells with MET amplification. PLoS ONE 8(10):e78656.
20. Ponzo MG, et al. (2009) Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci USA 106(31):12903-12908.
21. Knight JF, et al. (2013) Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer. Proc Natl Acad Sci USA 110(14): E1301-E1310.
22. Zagouri F, et al. (2013) High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer. Br J Cancer 108(5):1100-1105.
23. Weigelt B, Kreike B, Reis-Filho JS (2009) Metaplastic breast carcinomas are basal-like breast cancers: A genomic profiling analysis. Breast Cancer Res Treat 117(2):273-280.
24. Rottenberg S, et al. (2007) Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci USA 104(29):12117-12122.
25. Hennessy BT, et al. (2006) Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann Oncol 17(4):605-613.
26. Rottenberg S, et al. (2008) High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 105(44):17079-17084.
27. Mistry P, et al. (2001) In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res 61(2):749-758.
28. Jaspers JE, et al. (2013) Loss of 53BP1 causes PARP inhibitor resistance in Brca1- mutated mouse mammary tumors. Cancer Discov 3(1):68-81.
29. Prat A, et al. (2010) Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12(5):R68.
30. Gerhard R, et al. (2012) Immunohistochemical features of claudin-low intrinsic subtype in metaplastic breast carcinomas. Breast 21(3):354-360.
31. Jaspers JE, et al. (2015) BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance. Cancer Res 75(4):732-741.
32. Li H, Durbin R (2009) Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25(14):1754-1760.
33. ENCODE Project Consortium (2012) An integrated encyclopedia of DNA elements in the human genome. Nature 489(7414):57-74.
34. Szuhai K, Tanke HJ (2006) COBRA: Combined binary ratio labeling of nucleic-acid probes for multi-color fluorescence in situ hybridization karyotyping. Nat Protoc 1(1): 264-275.
35. Jonkers J, et al. (2001) Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 29(4):418-425.
36. Huang S, et al. (2012) MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. Cell 151(5):937-950.
37. Kinsella RJ, et al. (2011) Ensembl BioMarts: A hub for data retrieval across taxonomic space. Database (Oxford) 2011:bar030.